Jade Biosciences (JBIO) Income from Continuing Operations (2020 - 2026)
Jade Biosciences' (JBIO) quarterly Income from Continuing Operations came in at 40452000.0 in Q1 2026, down 5.98% YoY from 43025480.35 in Q1 2025, and down 15.65% on a QoQ basis from 34979000.0 in Q4 2025.
Powered by 
Analysis
Jade Biosciences (JBIO) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Jade Biosciences (JBIO) has 7 years of Income from Continuing Operations data on file, last reported at 40452000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 5.98% year-over-year to 40452000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 202138000.0 (down 58.43% YoY) and the FY2025 annual result came in at 178000.0, up 100.26% from the prior year.
- Income from Continuing Operations declined to 40452000.0 in Q1 2026, from 34979000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 10910000.0 in Q1 2022 to a low of 118081000.0 in Q1 2024.
- A 5-year average of 43438529.41 and a median of 40452000.0 in 2026 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations sank 452.25% — and 2025, when it soared 67.68%.
- Tracing JBIO's Income from Continuing Operations over 5 years: stood at 15782000.0 in 2022, then slumped by 40.57% to 22185000.0 in 2023, then slumped by 111.76% to 46979000.0 in 2024, then advanced by 25.54% to 34979000.0 in 2025, then dropped by 15.65% to 40452000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 40452000.0 (Q1 2026), 34979000.0 (Q4 2025), and 56706000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Jade Biosciences | 1.22 Bn | 1.22 Bn | - | -55.77 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -55.77 Mn |
| Mar 31, 2026 | -40.45 Mn |
| Dec 31, 2025 | -31.89 Mn |
| Sep 30, 2025 | -25.15 Mn |
| Jun 30, 2025 | -32.13 Mn |
| Mar 31, 2025 | -38.17 Mn |
| Dec 31, 2024 | -37.11 Mn |
| Sep 30, 2024 | -14.58 Mn |
| Jun 30, 2024 | -24.78 Mn |
| Mar 31, 2024 | -23.19 Mn |
| Dec 31, 2023 | -20.36 Mn |
| Sep 30, 2023 | -19.56 Mn |
| Jun 30, 2023 | -19.03 Mn |
| Mar 31, 2023 | -16.52 Mn |
| Dec 31, 2022 | -14.92 Mn |
| Sep 30, 2022 | -13.59 Mn |
| Jun 30, 2022 | -11.99 Mn |
| Mar 31, 2022 | -10.91 Mn |
| Dec 31, 2021 | -8.22 Mn |
| Sep 30, 2021 | -6.18 Mn |